Schneyer Mark C. 4

What Happened

• Mark C. Schneyer, Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), had 6,815 restricted stock units (RSUs) convert to common shares on May 1, 2026 (reported as a derivative exercise/conversion). Those shares were used to satisfy tax withholding (reported as a $0.00 disposition). On May 4, 2026 he sold 3,506 shares in an open‑market transaction for a weighted average price of $21.79, generating proceeds of $76,396. This activity is primarily routine (vesting and tax withholding) with a subsequent open‑market sale.

Key Details

• Transaction dates: RSU conversion and withholding — 2026-05-01; open‑market sale — 2026-05-04.
• Sale price: weighted average $21.79 (range reported $21.79 to $21.7932); total proceeds ≈ $76,396.
• Shares acquired via conversion: 6,815 RSUs converted to shares on 5/1 (footnote: each RSU = 1 share).
• Shares disposed for withholding: 6,815 shares reported disposed at $0.00 to cover taxes (sell‑to‑cover / withholding).
• Shares sold in market: 3,506 shares sold (open market).
• Shares owned after transaction: not listed in the Form 4 provided.
• Compliance notes: Mandatory withholding sale was made to cover taxes and is reported as intended to comply with Rule 10b5‑1; filing dated 2026-05-05 appears timely for the May 1–4 transactions.
• Vesting schedule: RSUs vest in four equal annual installments beginning May 1, 2024 (per footnote).

Context

• This was not a purchase signal — the primary events were RSU vesting and tax‑related withholding, followed by an open‑market sale of a portion of shares. For derivative/RSU transactions, a $0.00 disposition typically indicates shares were surrendered or withheld to pay taxes rather than sold for cash.